Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Correction to: Cell Discovery (2015) 1, 15040; doi:10.1038/celldisc.2015.40; published online 8 December 2015

In the initial published version of this article, there was an inadvertent omission from the Acknowledgements that the contribution of John P Cooke to this work was funded in part by a Core Facility Support Award from the Cancer Prevention and Research Institute of Texas (RP150611). This omission does not affect the description of the results or the conclusions of this paper.